Two novel quinoxaline-based EphA3 tyrosine kinase inhibitors have been designed and characterized in vivo in a relevant lymphoma model, showing high efficacy in the control of tumor size.
基于
喹啉衍生的两种新型EphA3
酪氨酸激酶
抑制剂已经设计并在相关淋巴瘤模型中进行了表征,显示出在控制肿瘤大小方面具有很高的功效。